ERIS - IntraDay Trade Analysis with Live Signals

Last Updated Time : 19 Sept 25, 2:16 pm

IntraDay Trade Rating: 2.7

📉 Intraday Trading Analysis — ERIS Lifesciences

🔍 Technical & Momentum Snapshot

Current Price: ₹1,638, trading below its 50-DMA (₹1,715) but above 200-DMA (₹1,535) — suggests short-term weakness.

RSI (28.9): Deeply oversold — could signal a bounce, but also reflects poor momentum.

MACD (-25.8): Strongly negative — confirms bearish trend.

Volume: 4.03 lakh vs 1-week avg of 2.95 lakh — above average, but likely driven by selling pressure.

52W Index: At 66.5%, the stock is mid-range in its yearly performance, not near breakout or support zones.

⚠️ Red Flags

Valuation: P/E of 139 vs industry average of 33.4 — extremely overvalued.

Fundamentals: ROCE (6.86%) and ROE (3.02%) are weak; debt-to-equity ratio of 0.89 is relatively high.

Momentum: RSI and MACD both suggest bearish sentiment.

Institutional Sentiment: FII holding declined (-0.04%) and DII increase is marginal (+0.11%).

📈 Intraday Strategy

🔹 If Entering Fresh Today

Avoid Entry: Momentum indicators and valuation do not support a bullish intraday setup.

If attempting a bounce trade

Buy Zone: ₹1,625–₹1,630 (only if RSI shows reversal and volume spikes)

Profit Targets

Target 1: ₹1,655 (minor resistance)

Target 2: ₹1,670 (if RSI >35 and MACD flattens)

Stop-Loss: ₹1,610 (below recent support)

🔹 If Already Holding

Exit on Weakness

RSI remains <30 and MACD continues downward

Price fails to hold above ₹1,630 with rising sell volume

Exit on Strength

Price breaks ₹1,655 with volume >1.5x average and RSI >35

Trail stop-loss upward to ₹1,640 once ₹1,655 is breached

🧠 Final Take

ERIS is not a strong intraday candidate today. Despite a sharp quarterly profit jump, technicals and valuation suggest caution. Only aggressive traders may attempt a bounce play — but risk is elevated.

Let me know if you'd like to track live RSI/MACD shifts or set alerts for reversal signals.

Edit in a page